-
Contextual factors influencing bubble continuous positive airway pressure implementation for paediatric respiratory distress in low-income and middle-income countries: a realist review. Lancet Global Health (IF 19.9) Pub Date : 2024-12-12 Nadir Ijaz,Marie Nader,Matthew Ponticiello,Ashlee J Vance,Brittney J van de Water,Melissa C Funaro,Qalab Abbas,John Adabie Appiah,Mohammod Jobayer Chisti,Walter Commerell,Suiyven Elvis Dzelamunyuy,Rudimar Martinez Fernandez,Anjelica L Gonzalez,Cintia Johnston,Evance Luckson Kaiwe,Manjinder Kaur,Hans-Joerg Lang,Eric D McCollum,José Marcos González Moraga,Jayashree Muralidharan,Kelsey Renning,Herng Lee
BACKGROUND Bubble continuous positive airway pressure (bCPAP) is a low-cost, non-invasive respiratory support therapy for children with respiratory distress, but its effectiveness is dependent on the context. We aimed to understand contextual factors influencing bCPAP implementation for children aged 1-59 months in low-income and middle-income countries (LMICs) and to develop a theory explaining how
-
Using theory to understand how interventions work and inform future implementation. Lancet Global Health (IF 19.9) Pub Date : 2024-12-12 Hamish R Graham,Jacquie Oliwa
-
Harm reduction must replace punitive drug policies Lancet Global Health (IF 19.9) Pub Date : 2024-12-05 The Lancet Global Health
-
The 2024 small island developing states report of the Lancet Countdown on health and climate change. Lancet Global Health (IF 19.9) Pub Date : 2024-12-04 Georgiana M Gordon-Strachan,Stephanie Y Parker,Heather C Harewood,Pablo A Méndez-Lázaro,Salanieta T Saketa,Kimalie F Parchment,Maria Walawender,Abdullahi O Abdulkadri,Paul J Beggs,Daniel F Buss,Riley J Chodak,Shouro Dasgupta,Olga De Santis,Natalie G Guthrie-Dixon,Saria Hassan,Harry Kennard,Sandeep B Maharaj,Kwesi G Marshall,Shelly R McFarlane,Kimberley S McKenzie,Maziar Moradi-Lakeh,Madhuvanti Murphy
-
Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Isaac Ravi Brenner,Clare F Flanagan,Martina Penazzato,Karen A Webb,Stephanie B Horsfall,Emily P Hyle,Elaine Abrams,Jason Bacha,Anne M Neilan,Intira Jeannie Collins,Sophie Desmonde,Siobhan Crichton,Mary-Ann Davies,Kenneth A Freedberg,Andrea L Ciaranello
BACKGROUND For children with HIV on antiretroviral therapy (ART), transitioning to dolutegravir-containing regimens is recommended. The aim of this study was to assess whether introducing viral load testing to inform new nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) for children with HIV and viraemia alongside dolutegravir-based ART is beneficial and of good economic value. METHODS
-
Urine-Xpert Ultra for the diagnosis of tuberculosis in people living with HIV: a prospective, multicentre, diagnostic accuracy study. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Bianca Sossen,Rita Székely,Madalo Mukoka,Monde Muyoyeta,Elizabeth Nakabugo,Jerry Hella,Hung Van Nguyen,Sasiwimol Ubolyam,Berra Erkosar,Marcia Vermeulen,Chad M Centner,Sarah Nyangu,Nsala Sanjase,Mohamed Sasamalo,Huong Thi Dinh,The Anh Ngo,Weerawat Manosuthi,Supunnee Jirajariyavej,Nhung Viet Nguyen,Anchalee Avihingsanon,Andrew D Kerkhoff,Claudia M Denkinger,Klaus Reither,Lydia Nakiyingi,Peter MacPherson
BACKGROUND Diagnostic delays for tuberculosis are common, with high resultant mortality. Urine-Xpert Ultra (Cepheid) could improve time to diagnosis of tuberculosis disease and rifampicin resistance. We previously reported on lot-to-lot variation of the Fujifilm SILVAMP TB LAM. In this prespecified secondary analysis of the same cohort, we aimed to determine the diagnostic yield and accuracy of Urine-Xpert
-
Postpartum maternal and infant haematological effects of second-trimester ferric carboxymaltose versus standard-of-care oral iron in Malawi: longitudinal follow-up of a randomised controlled trial. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Glory Mzembe,Ernest Moya,Martin N Mwangi,Ricardo Ataide,Rebecca Harding,Justina Kaunda,Truwah Zinenani,Gomezgani Mhango,William Stones,Owen Mtambo,Ayse Y Demir,Hans Verhoef,Sabine Braat,Sant-Rayn Pasricha,Kamija S Phiri
BACKGROUND Anaemia is common in mothers and infants in the first year postpartum, especially in sub-Saharan Africa. We evaluated whether treating anaemia in the second trimester of pregnancy with a single dose of intravenous iron, ferric carboxymaltose, compared with standard-of-care oral iron could alleviate anaemia in postpartum women and their infants. METHODS REVAMP (ACTRN12618001268235), an open-label
-
Understanding progress and challenges in women's health and wellbeing in exemplar countries: a time-series study identifying positive outliers. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Ira Martopullo,Paulo A Neves,Sarah Baird,Mengjia Liang,Emily C Keats,Alina Cherkas,Aditi Iyer,Shreelata Rao Seshadri,Emily Woolway,Cesar G Victora,Gita Sen,Jennifer Kidwell Drake,Zulfiqar A Bhutta
BACKGROUND Women's health and wellbeing (WHW) forms a multidimensional continuum across the life course, with intersecting power dynamics including socioeconomic and ethnic positioning. The WHW Exemplars project uses robust quantitative approaches to identify best-performing low-income and middle-income countries (LMICs) in improving WHW across the entire life course. METHODS Using the life course
-
The role and recognition of community health workers in research-a global survey. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 ,
-
The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort study. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Jacob Dubner,Alfred I Neugut,Maureen Joffe,Daniel S O'Neil,Oluwatosin A Ayeni,Wenlong Carl Chen,Ines Buccimazza,Sharon R Čačala,Laura W Stopforth,Hayley A Farrow,Sarah Nietz,Nivashini Murugan,Boitumelo Phakathi,Judith S Jacobson,Katherine D Crew,Valerie McCormack,Paul Ruff,Herbert Cubasch,Yoanna S Pumpalova
BACKGROUND Breast cancer is the most common malignancy diagnosed among women in South Africa, with the aggressive triple-negative subtype comprising approximately 15% of breast cancers in this population. South Africa has the largest population of people with HIV in the world. This study aims to evaluate the association between HIV status and the proportion of patients with breast cancer with the triple-negative
-
National and subnational burden of mental disorders in Iran (1990-2019): findings of the Global Burden of Disease 2019 study. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01
BACKGROUND Mental and behavioural disorders account for a large proportion of the burden of diseases in Iran. Identifying the pattern of change can help in policy making and provision of mental health services. We aimed to analyse the burden of mental disorders (excluding substance use disorders) in Iran at national and subnational levels with data from the Global Burden of Diseases, Injuries, and
-
The epidemiological benefit of pyrethroid-pyrrole insecticide treated nets against malaria: an individual-based malaria transmission dynamics modelling study. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Thomas S Churcher,Isaac J Stopard,Arran Hamlet,Dominic P Dee,Antoine Sanou,Mark Rowland,Moussa W Guelbeogo,Basiliana Emidi,Jacklin F Mosha,Joseph D Challenger,Adrian Denz,Andrew Glover,Giovanni D Charles,Emma L Russell,Rich Fitzjohn,Pete Winskill,Christen Fornadel,Tom Mclean,Peder Digre,Joseph Wagman,Frank Mosha,Jackie Cook,Martin C Akogbéto,Luc S Djogbenou,Hilary Ranson,Philip McCall,Alphaxard Manjurano
BACKGROUND Insecticide treated nets (ITNs) are the most important malaria prevention tool in Africa but the rise of pyrethroid resistance in mosquitoes is likely impeding control. WHO has recommended a novel pyrethroid-pyrrole ITN following evidence of epidemiological benefit in two cluster-randomised, controlled trials (CRTs). It remains unclear how effective more costly pyrethroid-pyrrole ITNs are
-
Reducing antibiotic use with diarrhoeal vaccines. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Kathy Leung,Joseph T Wu,Florian Marks
-
The impact of vaccines for diarrhoea on antibiotic use among children in five low-resource settings: a comparative simulation study. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Elizabeth T Rogawski McQuade,Stephanie A Brennhofer,Sarah E Elwood,Joseph A Lewnard,Jie Liu,Eric R Houpt,James A Platts-Mills
BACKGROUND Vaccines for diarrhoea could have the ancillary benefit of preventing antibiotic use. We aimed to quantify and compare the expected impact of enteric vaccines on antibiotic use via Monte Carlo simulations. METHODS We analysed data from a longitudinal birth cohort, which enrolled children from 2009 to 2012 from Bangladesh, India, Nepal, Pakistan, and Tanzania. We used Monte Carlo simulations
-
Ferric carboxymaltose: a potential game changer. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 John P A Lusingu,Emily Maisonet
-
Improving tuberculosis diagnosis in adults with HIV through Urine-Xpert Ultra. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Helena Rabie,Jantjie Taljaard
-
Family caregivers: an essential link in achieving health information equity. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Shahed Alam,Nazleen Bharmal,Edith Elliott
-
Quantifying the wellbeing of women: what metrics matter? Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Miriam Mutebi,Vandana Tripathi
-
HIFA response to the Lancet Global Health Editorial. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Neil Pakenham-Walsh,Geoff Royston,Chris Zielinski,
-
Documenting the burden of dementia in Africa: new approaches and key lessons. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Adesola Ogunniyi,Temitope H Farombi
-
Breastfeeding mothers in DR Congo should have access to the mpox vaccine. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Joachim Hombach,Rosamund Lewis,Judith van Holten,J Anthony Scott,Kathleen M Neuzil
-
Metrics for the people and by the people. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 The Lancet Global Health
-
Estimating dementia prevalence using remote diagnoses and algorithmic modelling: a population-based study of a rural region in South Africa. Lancet Global Health (IF 19.9) Pub Date : 2024-12-01 Meagan T Farrell,Darina T Bassil,Muqi Guo,M Maria Glymour,Ryan G Wagner,Stephen Tollman,Kenneth M Langa,Adam M Brickman,Jennifer J Manly,Lisa F Berkman
BACKGROUND Dementia is a leading cause of global death and disability. High-quality data describing dementia prevalence and burden remain scarce in sub-Saharan Africa. Health and Aging in Africa: A Longitudinal Study in South Africa (HAALSI) fills evidence gaps with longitudinal data on cognition, biomarkers, and everyday function in a population-based cohort of Black South Africans, aged 40 years
-
Effect of a community-based intervention for sexually transmitted infections on population-level prevalence among youth in Zimbabwe (STICH): a cluster-randomised trial. Lancet Global Health (IF 19.9) Pub Date : 2024-11-14 Chido Dziva Chikwari,Ethel Dauya,Victoria Simms,Katharina Kranzer,Tsitsi Bandason,Anna Machiha,Owen Mugurungi,Primrose Musiyandaka,Tinashe Mwaturura,Nkazimulo Tshuma,Sarah Bernays,Constancia Mavodza,Mandikudza Tembo,Kevin Martin,Constance R S Mackworth-Young,Joanna Busza,Suzanna C Francis,Richard J Hayes,Rashida A Ferrand
BACKGROUND Young people are at particularly high risk of acquiring sexually transmitted infections (STIs). We conducted a trial to investigate the effect of a community-based intervention that included STI screening among youth on population-level prevalence of STIs in Zimbabwe. METHODS STICH was a parallel-arm, cluster-randomised controlled trial nested within CHIEDZA, a trial of community-based integrated
-
Strategies for more equitable engagement for African researchers. Lancet Global Health (IF 19.9) Pub Date : 2024-11-14 Bamba Gaye,Ngoné Gaye,Gurbinder Singh,Naoufel Madani,Roberta Lamptey,Jamal Eddine Kohen,Abdoulaye Samb,Léon Tshilolo,Pasquale Maffia,Ibrahima Socé Fall,Modou Jobe
-
Estimates of resource use in the public-sector health-care system and the effect of strengthening health-care services in Malawi during 2015-19: a modelling study (Thanzi La Onse). Lancet Global Health (IF 19.9) Pub Date : 2024-11-13 Timothy B Hallett,Tara D Mangal,Asif U Tamuri,Nimalan Arinaminpathy,Valentina Cambiano,Martin Chalkley,Joseph H Collins,Jonathan Cooper,Matthew S Gillman,Mosè Giordano,Matthew M Graham,William Graham,Iwona Hawryluk,Eva Janoušková,Britta L Jewell,Ines Li Lin,Robert Manning Smith,Gerald Manthalu,Emmanuel Mnjowe,Sakshi Mohan,Margherita Molaro,Wingston Ng'ambi,Dominic Nkhoma,Stefan Piatek,Paul Revill,Alison
BACKGROUND In all health-care systems, decisions need to be made regarding allocation of available resources. Evidence is needed for these decisions, especially in low-income countries. We aimed to estimate how health-care resources provided by the public sector were used in Malawi during 2015-19 and to estimate the effects of strengthening health-care services. METHODS For this modelling study, we
-
Access to antibiotics for pneumonia and sepsis in LMICs Lancet Global Health (IF 19.9) Pub Date : 2024-11-11 Amy Sarah Ginsburg, Ken Duncan, Keith P Klugman, Padmini Srikantiah
-
Cost-effectiveness of a short-course antibiotic treatment strategy for the treatment of ventilator-associated pneumonia: an economic analysis of the REGARD-VAP trial Lancet Global Health (IF 19.9) Pub Date : 2024-11-04 Yiying Cai PhD, Suchart Booraphun MD, Andrew Yunkai Li MBBS, Gyan Kayastha MD, Prof Paul Anantharajah Tambyah PhD, Prof Ben S Cooper PhD, Prof Nicholas Graves PhD, Yin Mo DPhil
The REGARD-VAP trial showed that individualised shortened antibiotic therapy was non-inferior to usual care for mortality and pneumonia recurrence in patients with ventilator-associated pneumonia (VAP). We aimed to assess the cost-effectiveness of an individualised shortened antibiotic therapy approach in this planned economic analysis.
-
Women at the front line of the Marburg virus disease response in Rwanda: balancing clinical care, public health, and family life. Lancet Global Health (IF 19.9) Pub Date : 2024-11-04 Tsion Firew,Louise Mwiseneza,Malaika Asabwe,Ineza Nadine Vanessa,Marie Henriette Uwintwari,Françoise Nizeyimana,Doris Lorette Uwamahoro
-
Resolving the CD4-testing crisis to help end AIDS-related deaths. Lancet Global Health (IF 19.9) Pub Date : 2024-10-30 Omar Syarif,Rita Oladele,Tinne Gils,Radha Rajasingham,Jonathan Falconer,Pamela Achii,Edna Tembo,Donald Denis Tobaiwa,Kenneth Mwehonge,Charlotte Schutz,Nelesh P Govender,Graeme Meintjes,David B Meya,Angela Loyse
-
Africa's mpox strategic preparedness and response plan: a coordinated continental effort to boost health security. Lancet Global Health (IF 19.9) Pub Date : 2024-10-29 Nicaise Ndembi,Ngashi Ngongo,Moréniké Oluwátóyìn Foláyan,Jean Marie Yameogo,Fiona Braka,Salam Abdou Gueye,Moeti Matshidiso,Jean Kaseya
-
Machines matter too: including biomedical engineering partnerships in global health initiatives. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Tolulope Kehinde,Jesse Biwott,Gregory Sund,J Matthew Kynes
As the global burden of disease shifts from communicable to non-communicable diseases and trauma-related debility, the global health-care community has increasingly advocated for equitable access to surgical services. Much of this attention has focused on bolstering clinical and research expertise through the expansion of clinical training programmes and research resources. However, despite the crucial
-
Rapid surveys on violence against women in crisis contexts: decision-making guidance based on the UN Women Rapid Gender Assessment surveys on violence against women during COVID-19. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Raphaëlle Rafin,Nabamallika Dehingia,Juncal Plazaola-Castaño,Anita Raj
Rapid surveys or assessments offer the possibility to collect data in contexts where classic data collection is not feasible (such as health, humanitarian, or climate crises) and when evidence-based urgent action is needed to mitigate the effects of the crisis. Until the past 5 years, rapid surveys were not widely used by practitioners, researchers, or policy makers to measure the effect of crises
-
A loop-mediated isothermal amplification test for yaws: a multi-country diagnostic accuracy evaluation. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Becca L Handley,Camila González-Beiras,Serges Tchatchouang,Kouadio Aboh Hugues,Laud Antony Basing,Aboubacar Sylla,Mireille S Kouamé-Sina,Ivy Amanor,Philippe Ndzomo,Axel Aloumba,Mohammed Bakheit,Claudia Müller,Nadine Borst,Emelie Landmann,Helena Gmoser,Tamara Härpfer,Lisa Becherer,Simone Lüert,Sieghard Frischmann,Sarah Burl,Earnest Njih Tabah,Tania Crucitti,Adingra Tano Kouadio,Daniel Kojo Arhinful
BACKGROUND To meet the WHO target of eradicating yaws by 2030, highly sensitive and specific diagnostic tools are needed. A multiplex Treponema pallidum-Haemophilus ducreyi loop-mediated isothermal amplification (TPHD-LAMP) test holds promise as a near-patient diagnostic tool for yaws and H ducreyi. We conducted a prospective evaluation in Cameroon, Côte d'Ivoire, Ghana, and the Republic of the Congo
-
Safety of hepatitis E vaccine in pregnancy: an emulated target trial following a mass reactive vaccination campaign in Bentiu internally displaced persons camp, South Sudan. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Robin C Nesbitt,Andrew S Azman,Vincent Kinya Asilaza,Jessie K Edwards,Priscillah Gitahi,Patrick Nkemenang,Jetske Duncker,Melat Haile,Primitive Gakima,Joseph F Wamala,Fredrick Beden Loro,Duol Biem,Nelly Staderini,Manuel Albela,Monica Rull,John Rumunu,Iza Ciglenecki,Etienne Gignoux
BACKGROUND Epidemic forms of hepatitis E cause high mortality among pregnant people, with case fatality risks over 30% and adverse fetal outcomes. In 2022, the first mass reactive vaccination campaign against hepatitis E was conducted in South Sudan with the HEV239 vaccine. We aimed to assess whether vaccination against hepatitis E in pregnancy increases the risk of fetal loss in a cohort of vaccinated
-
Schistosome and malaria exposure and urban-rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Agnes Natukunda,Gyaviira Nkurunungi,Ludoviko Zirimenya,Jacent Nassuuna,Christopher Zziwa,Caroline Ninsiima,Josephine Tumusiime,Ruth Nyanzi,Milly Namutebi,Fred Kiwudhu,Govert J van Dam,Paul L A M Corstjens,Robert Kizindo,Ronald Nkangi,Joyce Kabagenyi,Beatrice Nassanga,Stephen Cose,Anne Wajja,Pontiano Kaleebu,Alison M Elliott,Emily L Webb,
BACKGROUND Vaccine immunogenicity and effectiveness vary geographically. Chronic immunomodulating parasitic infections including schistosomes and malaria have been hypothesised to be mediators of geographical variations. METHODS We compared vaccine-specific immune responses between three Ugandan settings (schistosome-endemic rural, malaria-endemic rural, and urban) and did causal mediation analysis
-
The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents (POPVAC C): an open-label, randomised controlled trial. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Jacent Nassuuna,Ludoviko Zirimenya,Gyaviira Nkurunungi,Agnes Natukunda,Christopher Zziwa,Caroline Ninsiima,Barbara Apule,Caroline Onen,Susan Amongi,Joel Serubanja,Pius Tumwesige,Denis Nsubuga,Rebecca Amongin,Govert J van Dam,Paul L A M Corstjens,John Kayiwa,Joyce Kabagenyi,Stephen Cose,Anne Wajja,Pontiano Kaleebu,Emily L Webb,Alison M Elliott,
BACKGROUND Immune responses induced by several important vaccines differ between populations, with reduced responses in low-income and rural settings compared with high-income and urban settings. BCG immunisation boosts immune responses to some unrelated vaccines in high-income populations. We aimed to test the hypothesis that BCG revaccination can enhance responses to unrelated vaccines in Ugandan
-
The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Ludoviko Zirimenya,Agnes Natukunda,Jacent Nassuuna,Gyaviira Nkurunungi,Christopher Zziwa,Caroline Ninsiima,Christine Kukundakwe,Christine M Nankabirwa,Charity Katushabe,Loyce K Namusobya,Gloria Oduru,Grace Kabami,Joel Kabali,John Kayiwa,Joyce Kabagenyi,Govert J van Dam,Paul L A M Corstjens,Stephen Cose,Anne Wajja,Sarah G Staedke,Pontiano Kaleebu,Alison M Elliott,Emily L Webb,
BACKGROUND Several important vaccines differ in immunogenicity and efficacy between populations. We hypothesised that malaria suppresses responses to unrelated vaccines and that this effect can be reversed-at least partially-by monthly malaria intermittent preventive treatment (IPT) in high-transmission settings. METHODS We conducted an individually randomised, double-blind, placebo-controlled trial
-
The effect of intensive praziquantel administration on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands (POPVAC A): an open-label, randomised controlled trial. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Gyaviira Nkurunungi,Jacent Nassuuna,Agnes Natukunda,Ludoviko Zirimenya,Bridgious Walusimbi,Christopher Zziwa,Caroline Ninsiima,Joyce Kabagenyi,Prossy N Kabuubi,Govert J van Dam,Paul L A M Corstjens,John Kayiwa,Moses Kizza,Alex Mutebe,Esther Nakazibwe,Florence A Akello,Moses Sewankambo,Samuel Kiwanuka,Stephen Cose,Anne Wajja,Pontiano Kaleebu,Emily L Webb,Alison M Elliott,
BACKGROUND Vaccine responses differ between populations and are often impaired in rural and low-income settings. The reasons for this are not fully understood, but observational data suggest that the immunomodulating effects of parasitic helminths might contribute. We hypothesised that Schistosoma mansoni infection suppresses responses to unrelated vaccines, and that suppression could be reversed-at
-
The lifetime risk of maternal near miss morbidity in Asia, Africa, the Middle East, and Latin America: a cross-country systematic analysis. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Ursula Gazeley,Antonino Polizzi,Julio Romero Prieto,José Manuel Aburto,Georges Reniers,Veronique Filippi
BACKGROUND Life-threatening maternal near miss (MNM) morbidity can have long-term consequences for the physical, psychological, sexual, social, and economic wellbeing of female individuals. The lifetime risk of MNM (LTR-MNM) quantifies the probability that a female individual aged 15 years will have an MNM before age 50 years, given current mortality and fertility rates. We compare the LTR-MNM globally
-
Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Gregory Barnsley,Daniela Olivera Mesa,Alexandra B Hogan,Peter Winskill,Andrew A Torkelson,Damian G Walker,Azra C Ghani,Oliver J Watson
BACKGROUND The COVID-19 pandemic has underscored the beneficial impact of vaccines. It also highlighted the need for future investments to expedite an equitable vaccine distribution. The 100 Days Mission aims to develop and make available a new vaccine against a future pathogen with pandemic potential within 100 days of that pathogen threat being recognised. We assessed the value of this mission by
-
Correction to Lancet Glob Health 2024; 12: e1794-806. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01
-
Hepatitis E vaccine and fetal loss: the potential pathophysiological basis - Authors' reply. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Asma Binte Aziz,Susanne Dudman,Khalequ Zaman,John D Clemens
-
Fixing the system to end violence against women. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 The Lancet Global Health
-
Hepatitis E vaccine and fetal loss: the potential pathophysiological basis. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Kuan Liu,Qiuwei Pan
-
Intensify praziquantel administration to reverse vaccine hyporesponsiveness in LMICs? Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Justin Komguep Nono
-
Maternal near misses: need for solid metrics and estimates. Lancet Global Health (IF 19.9) Pub Date : 2024-11-01 Kapila Jayaratne,Dulani Samaranayake
-
Strengthening health-care systems to reduce child mortality Lancet Global Health (IF 19.9) Pub Date : 2024-10-17 Abubakar Umar, Catherine E Oldenburg
-
Effect of a participatory whole-systems approach on mortality in children younger than 5 years in Jigawa state, Nigeria (INSPIRING trial): a community-based, parallel-arm, pragmatic, cluster randomised controlled trial and concurrent mixed-methods process evaluation Lancet Global Health (IF 19.9) Pub Date : 2024-10-17 Carina King PhD, Prof Rochelle Ann Burgess PhD, Ayobami A Bakare MPH, Funmilayo Shittu MSc, Julius Salako MPH, Damola Bakare MPH, Obioma C Uchendu MBA, Agnese Iuliano MSc, Nehla Djellouli PhD, Adamu Isah PhD, Ibrahim Haruna MSc, Samy Ahmar MSc, Tahlil Ahmed MSc, Paula Valentine MA, Temitayo Folorunso Olowookere MSc, Matthew MacCalla MSc, Hamish R Graham PhD, Eric D McCollum MD, James Beard BSc, Prof
In 2019, Nigeria reported the highest mortality rate in children younger than 5 years globally. We aimed to assess a whole-systems approach to improving child mortality in northern Nigeria.
-
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study Lancet Global Health (IF 19.9) Pub Date : 2024-10-11 Hongcheng Zhu PhD, Prof Melvin Lee Kiang Chua PhD, Prof Imjai Chitapanarux MD, Orit Kaidar-Person MD, Catherine Mwaba MD, Majed Alghamdi MD, Andrés Rodríguez Mignola MD, Natalia Amrogowicz MD, Prof Gozde Yazici MD, Zouhour Bourhaleb MD, Humera Mahmood FCPS, Prof Golam Mohiuddin Faruque MD, Muthukkumaran Thiagarajan MD, Abdelkader Acharki MD, Mingwei Ma MD, Martin Harutyunyan MD, Prof Hutcha Sriplung
Addressing the challenge of cancer control requires a comprehensive, integrated, and global health-system response. We aimed to estimate global radiotherapy demands and requirements for radiotherapy professionals from 2022 to 2050.
-
Modelling vaccination approaches for mpox containment and mitigation in the Democratic Republic of the Congo Lancet Global Health (IF 19.9) Pub Date : 2024-10-09 Alexandra Savinkina MSPH, Jason Kindrachuk PhD, Isaac I Bogoch MD, Prof Anne W Rimoin PhD, Nicole A Hoff PhD, Souradet Y Shaw PhD, Virginia E Pitzer ScD, Placide Mbala-Kingebeni MD, Gregg S Gonsalves PhD
Mpox was first identified in the Democratic Republic of the Congo (DRC) in 1970. In 2023, a historic outbreak of mpox occurred in the country, continuing into 2024. Over 14 000 cases and 600 deaths were reported in 2023 alone, representing a major increase from previous outbreaks. The modified vaccinia Ankara vaccine (brand names JYNNEOS, Imvamune, and Imvanex) was used in the 2022 mpox outbreak in
-
Do breastfeeding mothers in DR Congo have access to the mpox vaccine? Lancet Global Health (IF 19.9) Pub Date : 2024-10-07 Mija Ververs, Prince Imani-Musimwa, Karleen Gribble, David A Schwartz
-
Assessing the built environment through photographs and its association with obesity in 21 countries: the PURE Study Lancet Global Health (IF 19.9) Pub Date : 2024-09-27 Daniel J Corsi PhD, Simone Marschner MSc, Scott Lear PhD, Perry Hystad PhD, Prof Annika Rosengren PhD, Rosnah Ismail DrPH, Karen Yeates MD, Sumathi Swaminathan PhD, Thandi Puoane PhD, Chuangshi Wang PhD, Yang Li PhD, Sumathy Rangarajan MSc, Iolanthé M Kruger PhD, Jephat Chifamba DPhil, K Vidhu Kumar MD, Indu Mohan MD, Prof Kairat Davletov PhD, Prof Galina Artamonov PhD, Lia M Palileo-Villanueva MD
The built environment can influence human health, but the available evidence is modest and almost entirely from urban communities in high-income countries. Here we aimed to analyse built environment characteristics and their associations with obesity in urban and rural communities in 21 countries at different development levels participating in the Prospective Urban and Rural Epidemiology (PURE) Study
-
Accelerating the evidence for built environment health interventions Lancet Global Health (IF 19.9) Pub Date : 2024-09-27 Amanda Alderton
-
Correction to Lancet Glob Health 2024; published online Sept 23. https://doi.org/10.1016/S2214-109X(24)00320-6 Lancet Global Health (IF 19.9) Pub Date : 2024-09-26
-
The cause of nodding syndrome remains unknown Lancet Global Health (IF 19.9) Pub Date : 2024-09-25 Arthur W D Edridge, Michael Boele van Hensbroek
-
The cause of nodding syndrome remains unknown – Authors' reply Lancet Global Health (IF 19.9) Pub Date : 2024-09-25 Rodney Ogwang, Angela Vincent, Richard Idro
-
Intimate partner violence and childhood health outcomes in 37 sub-Saharan African countries: an analysis of demographic health survey data from 2011 to 2022 Lancet Global Health (IF 19.9) Pub Date : 2024-09-24 Abel F Dadi PhD, Kedir Y Ahmed PhD, Prof Yemane Berhane PhD, Habtamu Mellie Bizuayehu PhD, Getayeneh Antehunegn Tesema MPH, Tahir A Hassen PhD, Getiye Dejenu Kibret PhD, Daniel Bekele Ketema MPH, Meless G Bore MSc, Sewunet Admasu Belachew PhD, Erkihun Amsalu MSc, Sergio Nhassengo MPH, Desalegn Markos Shifti PhD, Abdulbasit Seid PhD, Yonatan M Mesfin PhD, Teketo Kassaw Tegegne PhD, Daniel Bogale Odo
Understanding the contribution of intimate partner violence (IPV) to childhood health outcomes (eg, morbidity and mortality) is crucial for improving child survival in sub-Saharan Africa. This comprehensive study aimed to explore the associations between maternal exposure to physical, sexual, or emotional violence and adverse childhood health outcomes in sub-Saharan Africa.
-
Maternal intimate partner violence and child health outcomes Lancet Global Health (IF 19.9) Pub Date : 2024-09-24 Rachel Jewkes, Mercilene Machisa
-
Delivery effectiveness of and adherence to intermittent preventive treatment for malaria in pregnancy with dihydroartemisinin-piperaquine with or without targeted information transfer or sulfadoxine-pyrimethamine in western Kenya: a three-armed, pragmatic, open-label, cluster-randomised trial. Lancet Global Health (IF 19.9) Pub Date : 2024-10-01 Hellen C Barsosio,Jayne Webster,Frederick Omiti,Alloys K'Oloo,Isdorah A Odero,Michael A Ojuok,Dawn Odiwa,Benson Omondi,Elizabeth Okello,James Dodd,Miriam Taegtmeyer,Feiko O Ter Kuile,Maia Lesosky,Simon Kariuki,Jenny Hill
BACKGROUND High-level resistance to sulfadoxine-pyrimethamine threatens the efficacy of WHO-recommended intermittent preventive treatment in pregnancy (IPTp) with single-dose sulfadoxine-pyrimethamine to prevent malaria. Monthly IPTp with dihydroartemisinin-piperaquine, a 3-day regimen, is an emerging alternative, but this regimen poses potential implementation and adherence challenges. We aimed to